EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, MIRM: Mirum Pharmaceuticals Inc

22 May 26 15:59
LAST:

98.62

CHANGE:
 2.05		OPEN:
100.67		HIGH:
101.66		ASK:
0.00		VOLUME:
172.6K
CHG(%):
2.04		PREV:
100.67		LOW:
98.24		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 May 26101.42101.6698.2498.62453.0K
21 May 2696.95101.9695.75100.67922.8K
20 May 2696.2399.9195.9596.95553.9K
19 May 2695.0798.5593.8795.651.31M
18 May 26102.19102.5694.3195.491.01M
15 May 26109.47110.25101.96102.191.67M
14 May 26109.16111.91106.01111.391.03M
13 May 26108.00114.99107.42109.166.52M
12 May 26106.97107.91103.59106.88662.8K
11 May 26106.78108.26104.71106.17528.4K

PROFILE

Name:Mirum Pharmaceuticals Inc
About:Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Sector:Healthcare
Industry:Biotechnology
Address:950 Tower Lane, Foster City, CA, United States, 94404
Website:https://www.mirumpharma.com
CUSIP:604749101
CIK:0001759425
ISIN:US6047491013
FIGI:BBG00MH7T2M7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-38.30 
Forward P/E:-885.33 
PEG Ratio:0.50 
Price to Sales:8.50 
Price to Book:15.85 
Profit Margin:-0.14 
Operating Margin:-0.04 
Return on Assets:-0.05 
Return on Equity:-0.24 
EPS Ratio:-0.47 
Revenue:429.16M 
Shares:60.34M 
Market Cap:5.951B 

TECHNICAL INDICATORS

MA5:97.481.2%
MA10:102.323.7%
MA20:101.472.9%
MA50:96.572.1%
MA100:95.493.3%
MA200:83.5318.1%
STO9:16.05 
STO14:16.05 
RSI14:42.04
WPR14:-80.31 
MTM14:-7.19
ROC14:-0.07 
ATR:6.25 
Week High:110.2511.8%
Week Low:93.875.1%
Month High:114.9916.6%
Month Low:88.3418.1%
Year High:114.9916.6%
Year Low:42.89129.9%
Volatility:25.01